Little Green Pharma advised of a media release relating to the analysis of the initial three-month results from the QUEST Initiative. Analysis of the initial three-month follow-up results from 2,327 Australian patients participating in the QUEST Initiative show: very strong evidence of clinically meaningful improvements for those suffering health-related quality of life (HRQL) and fatigue. Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements.

With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets. The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.